Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus Disease
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).